Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes

por Wolffenbuttel, B. H. R., Van Gaal, L., Durán‐Garcia, S., Han, J.
Publicado 2016

The Cushing Reflex: Oliguria as a Reflection of an Elevated Intracranial Pressure

por Leyssens, K., Mortelmans, T., Menovsky, T., Abramowicz, D., Twickler, Marcel Th. B., Van Gaal, L.
Publicado 2017

Health-related costs in a sample of premenopausal non-diabetic overweight or obese females in Antwerp region: a cost-of-illness analysis

por Hens, W., Vissers, D., Annemans, L., Gielen, J., Van Gaal, L., Taeymans, J., Verhaeghe, N.
Publicado 2018

Intensive insulin therapy in the intensive care unit: assessment by continuous glucose monitoring

por De Block, C, Rogiers, P, Manuel y Keenoy, B, Bervoets, K, Smet, M, Van Gaal, L
Publicado 2005

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

por Lean, M E J, Carraro, R, Finer, N, Hartvig, H, Lindegaard, M L, Rössner, S, Van Gaal, L, Astrup, A
Publicado 2014

Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed‐ratio combination: a post hoc analysis of the LixiLan‐O and LixiLan‐L tr...

por Davidson, J. A., Desouza, C., Fonseca, V., Frias, J. P., Van Gaal, L., Giorgino, F., Chao, J., Dex, T. A., Roberts, M., Saremi, A., Leiter, L. A.
Publicado 2019

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

por Astrup, A, Carraro, R, Finer, N, Harper, A, Kunesova, M, Lean, M E J, Niskanen, L, Rasmussen, M F, Rissanen, A, Rössner, S, Savolainen, M J, Van Gaal, L
Publicado 2012

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide

por Astrup, A, Carraro, R, Finer, N, Harper, A, Kunesova, M, Lean, M E J, Niskanen, L, Rasmussen, M F, Rissanen, A, Rössner, S, Savolainen, M J, Van Gaal, L
Publicado 2012

LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial

por Masmiquel, L., Leiter, L. A., Vidal, J., Bain, S., Petrie, J., Franek, E., Raz, I., Comlekci, A., Jacob, S., van Gaal, L., Baeres, F. M. M., Marso, S. P., Eriksson, M.
Publicado 2016